When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice
- 1 January 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 5 (1) , 6-11
- https://doi.org/10.1097/coh.0b013e32833384d3
Abstract
To review data related to the outcomes of antiretroviral therapy (ART) and the current operational experiences of ART programmes in low-income and middle-income countries (LMICs), concentrating on the implications and feasibility of changing ART initiation practice. ART initiation practice inhigh-income country settings has been modified in favour of starting ART earlier, basing on early evidence that HIV-associated morbidity and mortality are significantly reduced, and because there are increasingly more potent less toxic antiretroviral drug options available.In LMICs, ART initiation continues to follow conservative practice. At the same time, reports from ART programmes in low-income settings continue to demonstrate great benefits in terms of survival for people with HIV. However, compared with high-income country settings, the clinical outcomes of ART in LMICs are less favourable. The enormous HIV disease burden coupled with weaker health service capability is a key challenge to expanding ART effectively, although, as ART programmes mature, there are early indications that patient outcomes may be improving. In the immediate term, whether it is feasible to move to wide-scale earlier initiation of ART in LMICs remains in question; the priority for many countries is still equity and meeting the unmet needs for treatment. However, the possibility that early ART could reduce the risk of HIV transmission presents a particularly compelling incentive for earlier treatment in the high-burden settings of LMICs and further evidence on this rationale is anticipated from ongoing and planned studies.Keywords
This publication has 25 references indexed in Scilit:
- Loss to Follow-Up of Adults in Public HIV Care Systems in Central Mozambique: Identifying Obstacles to TreatmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Adult Clinical and Immunologic Outcomes of the National Antiretroviral Treatment Program in Rwanda During 2004-2005JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Five-Year Outcomes of the China National Free Antiretroviral Treatment ProgramAnnals of Internal Medicine, 2009
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalNew England Journal of Medicine, 2009
- Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe Lancet, 2009
- National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient OutcomesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Antiretroviral Treatment of Adult HIV InfectionJAMA, 2008
- Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART StudyThe Journal of Infectious Diseases, 2008
- Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal InsufficiencyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsThe Lancet, 2006